Skip to content

A Pilot Study of the Effects of Mindfulness-Based Cognitive Therapy on Positive Affect and Social Anxiety Symptoms

Marlene V. Strege, Deanna M. Swain, Lauren Ann Bochicchio, Andrew Valdespino, John A. Richey

Frontiers in Psychology June 1, 2018 DOI: 10.3389/fpsyg.2018.00866 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Open-label trial Randomized Pilot study Peer reviewed
Sample size 22
Population Adults meeting criteria for varied anxiety disorders, most with generalized anxiety disorder and/or social anxiety disorder
Intervention Mindfulness-based cognitive therapy (MBCT)
Duration 8-week intervention
Topics Anxiety Meditation
Citations 34
Key findings Improvements in positive affect, but not reductions in negative affect, predicted improvement in social anxiety symptoms after MBCT. Worry symptoms were instead predicted by decreased negative affect among individuals with generalized anxiety disorder, and by both decreased negative affect and increased positive affect in the full sample. The authors suggest MBCT may reduce social anxiety symptoms via improved positive affect, but note the findings are exploratory given the small, heterogeneous, uncontrolled sample.

Abstract

Randomized controlled trials have demonstrated that mindfulness-based cognitive therapy (MBCT) is efficacious in reducing residual depressive symptoms and preventing future depressive episodes (Kuyken et al., 2016). One potential treatment effect of MBCT may be improvement of positive affect (PA), due to improved awareness of daily positive events (Geschwind, Peeters, Drukker, Van Os, & Wichers, 2011). Considering social anxiety disorder (SAD) is characterized by diminished PA (Brown, Chorpita, & Barlow, 1998; Kashdan, 2007), we sought to determine whether MBCT would reduce social anxiety symptoms, and whether this reduction would be associated with improvement of PA deficits. Adults (N = 22) who met criteria for varied anxiety disorders participated in a small, open-label trial of an 8-week manualized MBCT intervention. Most participants presented with either a diagnosis (primary, secondary, or tertiary) of generalized anxiety disorder (GAD) (N = 15) and/or SAD (N = 14) prior to treatment, with eight individuals meeting diagnostic criteria for both GAD and SAD. We hypothesized participants would demonstrate improvements in social anxiety symptoms, which would be predicted by improvements in PA, not reductions in negative affect (NA). Results of several hierarchical linear regression analyses (completed in both full and disorder-specific samples) indicated that improvements in PA but not reductions in NA predicted social anxiety improvement. This effect was not observed for symptoms of worry, which were instead predicted by decreased NA for individuals diagnosed with GAD and both decreased NA and increased PA in the entire sample. Results suggest that MBCT may be efficacious in mitigating social anxiety symptoms, and this therapeutic effect may be linked to improvements in PA. However, further work is necessary considering the small, heterogeneous sample, uncontrolled study design, and exploratory nature of the study.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Citations in the library

Cited by 8

and 3 more in the library

Cites 18

and 13 more in the library

Explore topics